Certara, Inc. (NASDAQ:CERT) Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its position in Certara, Inc. (NASDAQ:CERT) by 4.5% during the second quarter, Holdings Channel reports. The fund owned 22,871 shares of the company’s stock after purchasing an additional 975 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Certara were worth $317,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Sei Investments Co. increased its holdings in shares of Certara by 12.4% in the 1st quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock worth $12,793,000 after acquiring an additional 79,013 shares during the period. Geneva Capital Management LLC increased its stake in Certara by 15.1% during the 1st quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after buying an additional 579,349 shares during the period. Wasatch Advisors LP increased its stake in Certara by 23.4% during the 1st quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock valued at $88,056,000 after buying an additional 932,598 shares during the period. Motley Fool Asset Management LLC increased its stake in Certara by 94.0% during the 1st quarter. Motley Fool Asset Management LLC now owns 96,792 shares of the company’s stock valued at $1,731,000 after buying an additional 46,897 shares during the period. Finally, Silvercrest Asset Management Group LLC increased its stake in Certara by 27.3% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 516,300 shares of the company’s stock valued at $9,231,000 after buying an additional 110,636 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. KeyCorp lowered their target price on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Barclays lowered their target price on shares of Certara from $16.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Tuesday. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Friday, September 27th. Robert W. Baird reduced their price objective on shares of Certara from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Finally, JMP Securities restated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Certara currently has an average rating of “Hold” and a consensus target price of $17.08.

Certara Price Performance

NASDAQ CERT opened at $11.57 on Friday. The company has a 50 day simple moving average of $11.64 and a 200-day simple moving average of $14.46. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of -29.67, a price-to-earnings-growth ratio of 5.40 and a beta of 1.49. Certara, Inc. has a 52-week low of $10.35 and a 52-week high of $19.87.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. Certara’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period last year, the company earned $0.10 earnings per share. Equities research analysts predict that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.

Insider Transactions at Certara

In other news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares of the company’s stock, valued at $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by insiders.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.